I 

113TH CONGRESS 

1ST SESSION H. R. 1285 

To amend the Controlled Substances Act to make any substance containing 

hydrocodone a schedule II drug. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 20, 2013 

Mr. BUCHANAN (for himself, Mr. MARKEY, Mrs. CAPITO, Mr. DIAZ-BALART, 

Mr. DUNCAN of Tennessee, Mr. MICA, Mr. ROE of Tennessee, Mr. ROGERS of Kentucky, Mr. ROONEY, Ms. ROS-LEHTINEN, Ms. BROWN of Florida, Mr. COOPER, Ms. EDWARDS, Mr. HASTINGS of Florida, Mr. 

KEATING, Mr. LYNCH, Mr. RAHALL, Ms. WILSON of Florida, Mr. KENNEDY, Mr. MURPHY of Florida, Ms. CASTOR of Florida, Mr. 

DESJARLAIS, Mr. FINCHER, Mr. MILLER of Florida, Mr. NUGENT, Mr. 

TIBERI, Mr. ISSA, Mr. DEUTCH, Mr. POSEY, Mrs. BLACK, Mr. PEARCE, 

Mr. MARINO, Ms. SLAUGHTER, Mr. WESTMORELAND, Mr. STIVERS, Mr. 

BENISHEK, Mr. CRENSHAW, Mr. ROSS, Mr. HIGGINS, Mr. 

SOUTHERLAND, Mr. TIPTON, Mr. SHUSTER, Mrs. MILLER of Michigan, 

Mr. RODNEY DAVIS of Illinois, and Mr. SCHOCK) introduced the following 

bill; which was referred to the Committee on Energy and Commerce, and 

in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such 

provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To amend the Controlled Substances Act to make any 

substance containing hydrocodone a schedule II drug. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


pwalker on DSK7TPTVN1PROD with BILLS
2 

•HR 1285 IH

1 SECTION 1. HYDROCODONE AMENDMENT. 

2 (a) IN GENERAL.—Schedule III(d) in section 202 of 

3 the Controlled Substances Act (21 U.S.C. 812) is amend4 ed by— 

5 (1) striking paragraphs (3) and (4); and 

6 (2) redesignating paragraphs (5), (6), (7), and 

7 (8) as paragraphs (3), (4), (5), and (6), respectively. 

8 (b) EFFECTIVE DATE.—The amendments made by 

9 subsection (a) shall take effect on the date that is 6 

10 months after the date of enactment of this Act. 

11 SEC. 2. PHYSICAL SECURITY REQUIREMENTS. 

12 Notwithstanding the amendments made by section 1, 

13 the Attorney General shall immediately, without regard to 

14 chapter 5 of title 5, United States Code, amend section 

15 1301.72 of title 21, Code of Federal Regulations, relating 

16 to the physical security controls for non-practitioners, nar17 cotic treatment programs and compounders for narcotic 

18 treatment programs, and storage areas for controlled sub19 stances, to allow, for the 3-year period beginning on the 

20 date of enactment of this Act, manufacturers and distribu21 tors to store hydrocodone compound products in accord22 ance with the physical security requirements for schedule 

23 III, IV, and V controlled substances. 

24 SEC. 3. GAO REPORT. 

25 (a) IN GENERAL.—Not later than 18 months after 

26 the date of enactment of this Act, the Comptroller General 


pwalker on DSK7TPTVN1PROD with BILLS
3 

•HR 1285 IH

1 of the United States shall submit to Congress a report 

2 on the reclassification of hydrocodone products under this 

3 Act. 

4 (b) CONTENTS.—The report required under sub5 section (a) shall include— 

6 (1) an assessment of the degree to which the 

7 reclassification of hydrocodone products under this 

8 Act impacts the ability of patients with legitimate 

9 medical needs, particularly those in rural areas and 

10 nursing home facilities, to access adequate pain 

11 management; and 

12 (2) recommendations necessary to address 

13 issues, if any, relating to patient access to adequate 

14 pain management. 

Æ 


pwalker on DSK7TPTVN1PROD with BILLS